AstraZeneta has announced new advances in a number of heavy-duty treatments

ASCO's annual meeting this year, AstraZeneca unveiled the latest advances in the treatment of lung cancer with a number of heavy-duty therapies. Happily, either the anti-PD-L1 immunotherapy Imfinzi (durvalumab) or the EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) can extend or hopefully extend the total survival of lung cancer patients.immunotherapy to treat lung cancer with a 3-year survival rate of 57%As a heavy-duty anti-PD-L1 immunotherapy, the latest data on Imfinzi's treatment of stage III non-small cell lung cancer were released today. Studies have shown that Imfinzi has long-lasting and significant survival benefits for patients who undergo chemotherapy (CRT) at the same time and have no progression in the disease.results came from the PACIFIC clinical trial. Last year, the New England Journal of Medicine published Imfinzi's two-year total lifetime data -- which reduced the risk of death by 32 percent, without taking into account PD-L1 expression levels. After an additional year of tracking, the latest results reach a similar conclusion.three-year data showed that patients who received both CRT and placebo had a survival rate of 43.5 percent. In patients who used both CRT and Imfinzi, survival increased to 57%. For the former, the total lifetime of the middle is 29.1 months. The latter's total middle lifetime data has not yet been obtained. Taken together, Imfinzi reduced the risk of death by 31% compared to placebos.AstraZeneca points out that Imfinzi is the only immunotherapy currently treated for non-removable stage III non-small cell lung cancer that demonstrates total lifetime benefits over a three-year period.researchers point out that the five-year survival rate for the disease is only 15 to 30 percent. In the current three-year results, more than half of the patients are still alive, which is gratifying.Tagrisso is expected to double the five-year survival rate of lung cancer AstraZeneca also presented a summary of its research on the heavy-weight therapy Tagrisso at the ASCO annual meeting. Previously, in FLAURA studies, Tagrisso achieved significantly longer progressive lifetimes than in controlled drugs in non-small cell lung cancer, which was positive for EGFR mutations. However, neither set of data is mature in the medium total lifetime.to better understand the long-term survival benefits of Tagrisso's first-line treatment for lung cancer patients, the researchers used mathematical models to predict a five-year clinically reasonable survival rate in FLAURA patients. Based on a model called Weybull, Tagrisso's medium total survival was about 41.4 months, better than the drug control group's 30.6 months. In addition, Tagrisso's three-year and five-year survival rates were 57.3 percent and 31.1 percent, respectively, better than the control group's 41.1 percent and 15.5 percent, respectively.
Based on the predictions of these models, the researchers noted that for non-small cell lung cancer, which is positive for EGFR mutations, Tagrisso's first-line treatment is expected to double the five-year total survival rate (31.1 percent to 15.5 percent). It is expected that future long-term follow-up data will further validate this finding and bring good news to patients. (Drug Ming Kant)